Kazia Therapeutics Ltd ADR (KZIA) Stock Price, Quote & News

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphom...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 2 9472 4101

Website: www.kaziatherapeutics.com

Address:

Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, Australia

LabMan Jan. 26 at 10:29 AM

$KZIA For the first time, outside of oncology drug development - data will be presented on paxalisib treatment for Parkinsons Disease. The presentation will take place here. The AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders will take place from March 17-21, 2026, in Copenhagen, Denmark. This conference is a significant event for professionals in the field, offering a platform to explore the latest research, clinical trials, and treatments for these diseases. It will feature a high-quality scientific program, a multidisciplinary community, and an International Scientific Advisory Board. There is no cure for PD, with the market expected US$8.5 billionPA. The study has been undertaken with financial support from the Michael J Fox Foundation and previous advice was that a clinical trial would follow. Highly significant news for the company.

1 · Reply

futureexmillionare Jan. 24 at 3:16 AM

$KZIA maybe the news is bigger then we thought ?

0 · Reply

StantheMan32 Jan. 24 at 2:40 AM

$KZIA New 13 G filing tonight. New 5.4% holder https://archive.fast-edgar.com/20260123/ADBOK22C8222W2ZU222V2MZZE8NCZ2S2Z282/

0 · Reply

reality90210 Jan. 24 at 1:50 AM

$KZIA 8.5M shares traded after hours. I smell something for Monday morning!

2 · Reply

Slider19200000 Jan. 23 at 11:27 PM

$KZIA new filing one new filing today Lynwood cap mgmt -5.4% equates to about 612K shares owned out of 11.3M shares o/s. wonder if this is one of the entities that purchased the $50M investment

1 · Reply

dunover Jan. 23 at 11:07 PM

$KZIA just remember, despite all the negativity around John Friend, he got investors in for $50M , yes shareholder dilution but: If these results were to be so defining to hit a $1B MC he would be criticised for giving the farm away. I suspect it’s more the investors have confidence that this will be big given a cash runway. This data should at least show the potential/reaffirm the drugs potential.

0 · Reply

KarlWolf Jan. 23 at 9:12 PM

$KZIA i wish everyone nothing but the best for the coming week!

0 · Reply

TW_Research Jan. 23 at 6:02 PM

$KZIA data next week. Similar MOA to $CELC different market cap, lol. I expect that gap to close rapidly. Sorry for earlier tweet tagging CELC. Right thought, wrong stock.

2 · Reply

PT3 Jan. 23 at 5:50 PM

$KZIA it’s time… enjoy!

0 · Reply

TW_Research Jan. 23 at 5:10 PM

$KZIA data next week. Similar MOA to $CALC. Slightly different market cap, lol. I expect that gap to close rapidly.

2 · Reply

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Dec 22, 2025, 8:00 AM EST - 4 weeks ago

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Dec 10, 2025, 8:00 AM EST - 6 weeks ago

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Dec 2, 2025, 12:21 PM EST - 7 weeks ago

What's Going On With Cancer Firm Kazia Therapeutics

Dec 2, 2025, 9:00 AM EST - 7 weeks ago

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Nov 18, 2025, 4:15 PM EST - 2 months ago

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Oct 27, 2025, 7:15 AM EDT - 3 months ago

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Oct 7, 2025, 8:30 AM EDT - 3 months ago

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

Oct 2, 2025, 8:30 AM EDT - 4 months ago

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Oct 1, 2025, 9:21 AM EDT - 4 months ago

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Sep 11, 2025, 8:00 AM EDT - 4 months ago

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

Aug 1, 2025, 8:00 AM EDT - 6 months ago

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

Jul 9, 2025, 8:00 AM EDT - 7 months ago

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Jun 11, 2025, 8:00 AM EDT - 8 months ago

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

May 15, 2025, 8:00 AM EDT - 9 months ago

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Mar 31, 2025, 7:30 AM EDT - 10 months ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Jan 30, 2025, 7:30 AM EST - 1 year ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Jan 14, 2025, 4:00 PM EST - 1 year ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Jan 10, 2025, 9:58 AM EST - 1 year ago

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Dec 31, 2024, 12:34 PM EST - 1 year ago

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Dec 31, 2024, 8:00 AM EST - 1 year ago

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Dec 11, 2024, 8:00 AM EST - 1 year ago

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Nov 4, 2024, 7:30 AM EST - 1 year ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Oct 2, 2024, 8:45 AM EDT - 1 year ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Sep 12, 2024, 7:30 AM EDT - 1 year ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Jul 10, 2024, 12:24 PM EDT - 1 year ago

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Jun 27, 2024, 8:15 AM EDT - 1 year ago

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

May 23, 2024, 2:41 PM EDT - 1 year ago

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

May 1, 2024, 8:45 AM EDT - 1 year ago

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Mar 21, 2024, 8:52 AM EDT - 2 years ago

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Kazia announces presentation of new data at AACR Annual Meeting

Feb 21, 2024, 7:30 AM EST - 2 years ago

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Jan 18, 2024, 7:30 AM EST - 2 years ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Dec 5, 2023, 6:02 PM EST - 2 years ago

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Dec 1, 2023, 8:00 AM EST - 2 years ago

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Nov 29, 2023, 7:01 AM EST - 2 years ago

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Nov 21, 2023, 7:30 AM EST - 2 years ago

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 20, 2023, 4:30 PM EST - 2 years ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Nov 15, 2023, 8:30 AM EST - 2 years ago

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 10, 2023, 7:01 AM EST - 2 years ago

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

Nov 1, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA

Oct 23, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Oct 11, 2023, 7:01 AM EDT - 2 years ago

Kazia announces voluntary delisting from ASX

Oct 5, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

Sep 29, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Jul 6, 2023, 7:00 AM EDT - 2 years ago

KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY

Jun 8, 2023, 7:00 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

LabMan Jan. 26 at 10:29 AM

1 · Reply

futureexmillionare Jan. 24 at 3:16 AM

$KZIA maybe the news is bigger then we thought ?

0 · Reply

StantheMan32 Jan. 24 at 2:40 AM

$KZIA New 13 G filing tonight. New 5.4% holder https://archive.fast-edgar.com/20260123/ADBOK22C8222W2ZU222V2MZZE8NCZ2S2Z282/

0 · Reply

reality90210 Jan. 24 at 1:50 AM

$KZIA 8.5M shares traded after hours. I smell something for Monday morning!

2 · Reply

Slider19200000 Jan. 23 at 11:27 PM

$KZIA new filing one new filing today Lynwood cap mgmt -5.4% equates to about 612K shares owned out of 11.3M shares o/s. wonder if this is one of the entities that purchased the $50M investment

1 · Reply

dunover Jan. 23 at 11:07 PM

0 · Reply

KarlWolf Jan. 23 at 9:12 PM

$KZIA i wish everyone nothing but the best for the coming week!

0 · Reply

TW_Research Jan. 23 at 6:02 PM

$KZIA data next week. Similar MOA to $CELC different market cap, lol. I expect that gap to close rapidly. Sorry for earlier tweet tagging CELC. Right thought, wrong stock.

2 · Reply

PT3 Jan. 23 at 5:50 PM

$KZIA it’s time… enjoy!

0 · Reply

TW_Research Jan. 23 at 5:10 PM

$KZIA data next week. Similar MOA to $CALC. Slightly different market cap, lol. I expect that gap to close rapidly.

2 · Reply

PT3 Jan. 23 at 4:25 PM

$KZIA just bought some more.

1 · Reply